Sign In
Buy PRPO
$21.65
+0.460 (+2.17%)
At Close: Jul 31, 2026
Mr. Richard Sandberg is appointed Chairman of Precipio's Board of Directors
11:00am, Wednesday, 03'rd Mar 2021
NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board
Precipio Launches COVID-19 Antibody Testing at Point-of-Care
09:30am, Thursday, 28'th Jan 2021
Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC
Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
10:00am, Wednesday, 20'th Jan 2021
Partnership with ION Solutions expected to accelerate sales Partnership with ION Solutions expected to accelerate sales
Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor
10:15am, Thursday, 10'th Dec 2020
Thousands of Oncology Practices will gain access to HemeScreen POL program Thousands of Oncology Practices will gain access to HemeScreen POL program
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q3 2020 Results - Earnings Call Transcript
09:43pm, Thursday, 19'th Nov 2020
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q3 2020 Results - Earnings Call Transcript
Precipio Announces Q3-2020 Shareholder Update Call
09:00am, Wednesday, 11'th Nov 2020
Conference Call to be held on Thursday, November 19th, 2020 at 5:00 PM EST Conference Call to be held on Thursday, November 19th, 2020 at 5:00 PM EST
